Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the EU, UK and Switzerland.

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn.

Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon Therapeutics, meaning it is now a wholly owned subsidiary of Merck.

Johnson & Johnson has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger transaction with a total equity value of approximately $2bn.

Novartis has announced that it has entered an agreement to acquire Morphosys AG for €2.7bn, or €68 per share.

Zuellig Pharma has announced that it has completed the acquisition of two brands, Cialis (tadalafil) and Alita (pemetrexed), from Eli Lilly for selected ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand.

Jazz Pharmaceuticals and Redx Pharma have announced that the companies have signed a definitive agreement under which Jazz will acquire Redx’s kirsten rat sarcoma virus (KRAS) inhibitor programme.

C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca, which was triggered by the preclinical progress of C4XD’s NRF2 activator programme.

GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an initial $1bn upfront payment along with up to $400m in success-based regulatory milestone payments.

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following the spin-off of non-inbrx-101 assets into New Inhibrx.

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a definitive agreement for Merck, through a subsidiary, to acquire Harpoon for an approximate total equity value of $680m or $23 per share.

Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz Pharmaceuticals for up to $770.5m, with the intention of discovering and developing drug candidates to target two different ion channel targets associated with neurological disorders.